Clinical Significance and Effect of IncRNA HOXA11-AS in NSCLC: A Study Based on Bioinformatics, *In Vitro* and *in Vivo* Verification

Yu Zhang¹, Wen-jie Chen², Ting-qing Gan¹, Xiú-ling Zhang¹, Zu-cheng Xie¹, Zhi-hua Ye¹, Yun Deng¹, Ze-feng Wang¹, Kai-teng Cai¹, Shi-kang Li², Dian-zhong Luo¹ & Gang Chen¹

HOXA11 antisense RNA (HOXA11-AS) has been shown to be involved in tumorigenesis and development of different cancers. However, the role of HOXA11-AS in non-small cell lung cancer (NSCLC) remains unclear. In this study, we firstly explored and confirmed the expression of HOXA11-AS in NSCLC tissues and cells. Cytometry, CCK-8, cell scratch, migration, Matrigel invasion and flow cytometry assays were performed to determine the biological impact of HOXA11-AS *in vitro*. Furthermore, a chick embryo chorioallantoic membrane (CAM) model of NSCLC was constructed to explore the effect of HOXA11-AS on tumorigenicity and angiogenesis *in vivo*. Additionally, bioinformatics analyses were performed to investigate the prospective pathways of HOXA11-AS co-expressed genes. As results, HOXA11-AS was markedly highly expressed in NSCLC tissues and cells. Furthermore, the proliferation, migration, invasion, tumorigenic and angiogenic ability of NSCLC cells were all inhibited and apoptosis was induced after HOXA11-AS knock-down. HOXA11-AS RNAi also led to cell cycle arrest on G0/G1 or G2/M phase. In addition, the non-small cell lung cancer pathway might be involved in regulating the co-expressed genes of HOXA11-AS in NSCLC. These results indicate that HOXA11-AS plays pivotal roles in NSCLC and it can become a novel therapeutic direction for treating NSCLC.

Lung cancer, which comprises small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), is the predominant cause of cancer deaths globally, and the incidence rate ranks first among all malignancies¹–⁴. NSCLC accounts for approximately 80% of lung cancer, and currently, it still has an unsatisfactory prognosis despite the advances made in its treatments, with an overall 5-year survival rate of less than 16%⁵–⁷. Therefore, a deeper understanding of the underlying molecular mechanisms related to NSCLC is of great importance.

Long non-coding RNAs (lncRNAs) are non-coding transcripts with length greater than 200 nucleotides that share similarities with messenger RNAs (mRNAs)⁸. They have no significant protein-coding capabilities but play an important part in the modification of various biological and pathological processes, such as tumor growth, metastasis, differentiation and immune response⁹–¹². LncRNAs can also contribute to carcinogenesis or tumor suppression and play a role in regulating cell cycle, apoptosis, proliferation, invasion and migration through their aberrant expression in different cancers¹¹–¹³. To date, the effect and mechanism of many lncRNAs in NSCLC has been reported. For example, MALAT-1 acts as an oncogene and is highly expressed in NSCLC tissues and cell lines. The migration and growth of tumors was inhibited after silencing MALAT-1 expression¹⁴,¹⁵, whereas the forced expression of MALAT-1 significantly increased migration in NSCLC cells¹⁶. In addition, MALAT-1 directly regulated the expression of Bcl-2 to effect prognosis of NSCLC¹⁷. Some reports have revealed that lncRNAs play an important role in cancers via targeting miRNAs and regulating genes. For instance, PCA3

¹Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Guangxi Zhuang Autonomous Region, Nanning, 530021, China. ²Department of Thoracic and Cardiovascular Surgery, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Guangxi Zhuang Autonomous Region, Nanning, 530021, China. ³Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Guangxi Zhuang Autonomous Region, Nanning, 530021, China. Yu Zhang and Wen-jie Chen contributed equally to this work. Correspondence and requests for materials should be addressed to D.-z.L. (email: 13878802796@163.com) or G.C. (email: chen_gang_triones@163.com)
up-regulated the expression of PRKD3 by miR-1261 sponging to promote invasion and migration of prostate cancer cells. Moreover, MALAT-1 inhibited proliferation, migration and invasion of esophageal squamous cell carcinoma cells via regulation of the expression of miR-101 and miR-217.

LncRNA HOXA11 antisense RNA (HOXA11-AS), also identified as HOXA-AS5, HOXA11S, HOXA11-AS1, HOXA11AS, or NCRNA00076, is located on 7p15.2 with the NCBI Gene ID: 221883. HOXA11-AS is one of the homeobox (HOX) family genes, and the length of HOXA11-AS is 3885 nt. Interestingly, no HOXA11-AS expression was found in normal lung tissues (http://rna.sysu.edu.cn/deepBase/). Previously, we have investigated the expression and the underlying pathways of HOXA11-AS in NSCLC based on the Cancer Genome Atlas (TCGA) database and bioinformatics analyses (gene ontology (GO), pathway, Kyoto Encyclopedia of Genes and Genomes (KEGG), and network analyses). As results, we found that HOXA11-AS was significantly over-expressed in both lung adenocarcinoma and squamous cell carcinoma based on TCGA database. In addition, the high area under curve (AUC) of HOXA11-AS indicates a potential diagnostic value of HOXA11-AS level in NSCLC. Also, the bioinformatics analyses show that HOXA11-AS may play a significant role in development.
and progression of NSCLC via regulating various pathways and genes. However, the exact mechanism should be verified by functional experiments. In this study, we aimed to explore the effect of HOXA11-AS on proliferation, migration, invasion and apoptosis of NSCLC in vitro and in vivo. The TCGA database was used to verify the differential expression of HOXA11-AS between normal lung and NSCLC tissues. Quantitative reverse transcription–polymerase chain reaction (qRT-PCR), lentivirus-mediated HOXA11-AS RNAi transfection, flow cytometry and CCK-8, cell scratch, migration, and Matrigel invasion assays were performed, as well as development of a chick embryo chorioallantoic membrane (CAM) model, to clarify the possible role of HOXA11-AS in NSCLC. In addition, Multi Experiment Matrix (MEM) was used to analyze the potential pathways associated with HOXA11-AS.

**Results**

**HOXA11-AS expression in NSCLC.** To further explore the difference of HOXA11-AS expression between NSCLC compared with non-cancerous lung tissues, we performed clinical research using the original data in TCGA. Two NSCLC cohorts, which comprised lung adenocarcinoma patients (287 lung adenocarcinoma cases vs 12 non-cancerous lung cases) and lung squamous cell carcinoma patients (463 lung squamous cell carcinoma cases vs 12 non-cancerous lung cases) were extracted. Increased expression of HOXA11-AS was observed in lung adenocarcinoma tissues (3.173 ± 2.059) and lung squamous cell carcinoma tissues (5.049 ± 1.919) compared with...
the non-cancerous tissues (1.340 ± 0.466, 1.780 ± 0.349, respectively, both P < 0.001, Fig. 1A, B). With regard to the clinicopathological characteristics, we found that HOXA11-AS expression was higher (3.790 ± 2.143) in stage (III + IV) than in stage (I + II) (3.031 ± 2.025, P = 0.01, Fig. 1C) in lung adenocarcinoma as well as in lung squamous cell carcinoma (III + IV: 5.569 ± 1.980, I + II: 4.939 ± 1.896, P = 0.01, Fig. 1D). For the other clinicopathological parameters, no statistical associations were found based on TCGA database. Meanwhile, the area under the curve (AUC) of HOXA11-AS reached 0.811 (95% CI: 0.729–0.893, P < 0.0001, Fig. 1E) in lung adenocarcinoma and 0.952 (95% CI: 0.930–0.975, P < 0.0001, Fig. 1F) in lung squamous cell carcinoma, which indicate a high diagnostic value of the HOXA11-AS level in lung cancer. In addition, we investigated the prognostic significance of HOXA11-AS in the two cohorts of NSCLC patients in TCGA. We observed a trend in which low HOXA11-AS expression was correlated with a better survival (112.13 ± 16.09 months) compared to the high HOXA11-AS expression group (69.80 ± 11.32 months, P = 0.007, Fig. 1G) in lung adenocarcinoma, but no obvious trend was noted in lung squamous cell carcinoma (P = 0.988, Fig. 1H). Furthermore, an up-regulated trend in HOXA11-AS level in NSCLC tissues (2.621 ± 0.533) was found compared to corresponding non-cancerous lung tissues (1.121 ± 0.197, P = 0.014, Fig. 2A) based on qRT-PCR. In addition, the diagnostic value of the HOXA11-AS level in NSCLC was assessed by a receiver operating characteristic (ROC) curve and the AUC of HOXA11-AS was 0.692 (95% CI: 0.521–0.864, P = 0.037, Fig. 2B). We also explored the correlation between HOXA11-AS and gender or age, but no significant correlation was found in either lung adenocarcinoma or squamous cell carcinoma. This might partially be due to the limited sample size.

In addition, we also determined the expression level of HOXA11-AS among 4 NSCLC cell lines (PC9, A549, H460 and H1299). Consistent with the results in NSCLC tissues, an increased HOXA11-AS level was found in the 4 cell lines, especially in A549 cells (t = −22.242, P = 0.002), compared to human bronchial epithelial cells (all P < 0.05, data not shown).

Figure 4. HOXA11-AS RNAi inhibited the proliferation of A549, H460, H1299 and PC9 cell lines (**P < 0.05, ***P < 0.01, ****P < 0.001). (Note: control, lenti-control virus) The proliferation of A549, H460, H1299 and PC9 cell lines was inhibited based on a cytometry assay (A) and CCK-8 assay (B).
The effect of HOXA11-AS on proliferation, migration, invasion, apoptosis and cell cycle in NSCLC in vitro. To explore the underlying effect of HOXA11-AS on biological processes in NSCLC, lentivirus-mediated HOXA11-AS RNAi was constructed. Thus, we observed the transfection efficiency of HOXA11-AS RNAi under a light microscope and fluorescence microscope. We found that the transfection efficiency of HOXA11-AS RNAi group in NSCLC cell lines was over 80%, and the knockdown efficiency of HOXA11-AS was over 75%. Furthermore, real time RT-qPCR was used to detect the expression of HOXA11-AS in different groups, and we found that HOXA11-AS expression was significantly lower in HOXA11-AS RNAi groups than in control groups (P < 0.01, Fig. 3A). In A549 cells, the expression of HOXA11-AS was remarkably reduced after transfection with HOXA11-AS RNAi (t = 25.53, P = 0.002). The light microscope and fluorescence microscope images after transfection with lenti-control virus and HOXA11-AS RNAi are shown in Fig. 3B. Similar to A549 cells, a significant decrease after transfection with HOXA11-AS RNAi was observed in the other 3 cell lines (PC9, H460 and H1299) (data not shown).
Table 2. Effect of HOXA11-AS RNAi on proliferation of NSCLC A549 cell line, determined by CCK-8 assay. t values were obtained by comparison with the negative control.

| Time | Control | HOXA11-AS RNAi-54 | HOXA11-AS RNAi-55 | HOXA11-AS RNAi-56 |
|------|---------|-------------------|-------------------|-------------------|
|      | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | t      | p      | t      | p      | t      | p      | t      | p      |
| 2h   | 0.219 ± 0.001 | 0.221 ± 0.003 | 0.221 ± 0.002 | 0.230 | 0.222 ± 0.015 | −1.342 | 0.251 | 0.221 ± 0.002 | −1.414 | 0.251 | 0.222 ± 0.015 | −2.475 | 0.069 |
| 24h  | 0.369 ± 0.158 | 0.324 ± 0.018 | 0.346 ± 0.016 | 2.335 | 0.353 ± 0.007 | 4.143 | 0.003 | 0.364 ± 0.017 | 2.335 | 0.048 | 0.353 ± 0.007 | 2.087 | 0.07 |
| 48h  | 0.494 ± 0.021 | 0.411 ± 0.033 | 0.402 ± 0.009 | 8.875 | <0.001 | 0.451 ± 0.015 | 2.335 | 0.008 | 0.402 ± 0.009 | 8.875 | <0.001 | 0.451 ± 0.015 | 2.335 | 0.008 |
| 72h  | 0.818 ± 0.068 | 0.531 ± 0.074 | 0.552 ± 0.018 | 3.334 | <0.001 | 0.531 ± 0.074 | 6.334 | <0.001 | 0.552 ± 0.018 | 3.334 | <0.001 | 0.531 ± 0.074 | 6.334 | <0.001 |
| 96h  | 1.816 ± 0.138 | 0.757 ± 0.031 | 0.886 ± 0.011 | 16.738 | <0.001 | 0.757 ± 0.031 | 16.738 | <0.001 | 0.886 ± 0.011 | 16.738 | <0.001 | 0.757 ± 0.031 | 16.738 | <0.001 |
To further evaluate the proliferation of cells in 3 different groups (blank control, lenti-control virus group and HOXA11-AS RNAi group), cytometry and CCK-8 assays were performed. We observed a significant inhibition in proliferation in the HOXA11-AS RNAi group of all (A549, H460, 1299 and PC9) cell lines compared to control groups (Fig. 4). In the cytometry assay, the proliferation of the HOXA11-AS RNAi group was clearly suppressed ($P < 0.05$), although a minor difference was observed between the different HOXA11-AS RNAi groups (HOXA11-AS RNAi-54, HOXA11-AS RNAi-55, HOXA11-AS RNAi-56). A more obvious suppression of proliferation was found in HOXA11-AS RNAi-54 and HOXA11-AS RNAi-55 groups compared with HOXA11-AS RNAi-56 groups in A549, H460 and PC9 cell lines, whereas proliferation of H1299 cells was clearly found to be inhibited in HOXA11-AS RNAi-56 groups. Specifically, in A549 cells, no obvious difference was found between HOXA11-AS RNAi-54 and HOXA11-AS RNAi-55 groups compared with control groups on the first day. Whereas, on the second day, the proliferation of HOXA11-AS RNAi-54 and HOXA11-AS RNAi-55 groups was remarkably reduced ($P < 0.05$). Then, on days 3 to 7, the proliferation was also obviously reduced in HOXA11-AS RNAi-54 and HOXA11-AS RNAi-55 groups ($P < 0.01$). In the HOXA11-AS RNAi-56 group, no obvious difference was found on the first day ($P = 0.591$), whereas a significant decrease was found on days 2 to 7 ($P < 0.05$, Table 1). Comparable results were achieved in the other 2 cell lines (PC9 and H460, data not shown). For H1299 cells, the strongest inhibition was found in the HOXA11-AS RNAi-56 group ($P < 0.01$, data not shown). To verify the results of the cytometry assay, a cell counting kit-8 (CCK-8) assay was performed, and similar conclusions were demonstrated by the CCK-8 assay in A549 cells (Table 2). Knockdown of HOXA11-AS inhibited the proliferation of the 4 NSCLC cell lines. The HOXA11-AS RNAi-54 groups exhibited obvious proliferation suppression in A549, H460 and PC9 cell lines, consistent with the HOXA11-AS RNAi-55 group ($P < 0.001$). However, the HOXA11-AS RNAi-56 group showed the most significant inhibition in H1299 cells ($P < 0.001$, data not shown). Based on these results, we can conclude that HOXA11-AS markedly increases the proliferation of these 4 NSCLC cell lines.

Then, a cell scratch assay was performed to further explore the effect of HOXA11-AS RNAi on the migration ability of NSCLC cells. The results demonstrated that the migration ability was significantly inhibited after knockdown of HOXA11-AS, especially in A549 cells ($P < 0.01$, Fig. 5A). In addition, among the 3 HOXA11-AS RNAi groups, the HOXA11-AS RNAi-54 group was found to have the strongest ability to suppress migration at 48h ($P < 0.001$, Fig. 5C). Similar results were obtained in H460, H1299 and PC9 cell lines ($P < 0.05$, Fig. 5B,D). Overall, these results indicated that the migration of NSCLC cells was inhibited due to knockdown of HOXA11-AS. Furthermore, a Transwell migration assay was used to further verify the results of the cell scratch assay. Consistent with the cell scratch assay, the migration ability in the HOXA11-AS RNAi-54 group was remarkably suppressed in the A549 cell line compared to the control group ($P = 0.007$, Fig. 6A). A similar inhibition of migration was found in H460 and PC9 cell lines ($P < 0.01$), whereas in H1299 cells, the HOXA11-AS RNAi-56 group demonstrated the strongest inhibition effect ($P = 0.026$, Fig. 6B). We can conclude that HOXA11-AS significantly promotes the migration of NSCLC cells.
Furthermore, the effect of HOXA11-AS RNAi on invasion ability was detected in NSCLC cells using a Transwell invasion assay. In A549 cells, we demonstrated that HOXA11-AS RNAi could reduce cell invasion ability, compared to control groups (P < 0.001, Fig. 7A). Additionally, a more remarkable inhibition was found in the HOXA11-AS RNAi-54 group than in the HOXA11-AS RNAi-55 group (P = 0.033, Fig. 7B). Similar results were found in H460, H1299 and PC9 cell lines (data not shown).

Afterwards, we focused on the effect of HOXA11-AS on cell apoptosis in these 4 NSCLC cell lines (A549, H460, H1299 and PC9) via a flow cytometry assay. After being transfected with HOXA11-AS RNAi, an increased number of apoptotic cells and dead cells could be observed under a light microscope, indicating that HOXA11-AS RNAi could significantly promote apoptosis in NSCLC cells (Fig. 8). To further verify the acceleration effect of HOXA11-AS RNAi on apoptosis, Annexin V-PE/7-AAD staining was performed to measure cell apoptosis in these 4 NSCLC cell lines. In A549 cells, we found that the cell apoptotic rate increased in the groups that were transfected with HOXA11-AS RNAi (7.26 ± 1.94%) and HOXA11-AS RNAi-55 (5.15 ± 0.74%) compared to those in the lenti-control virus group (1.72 ± 0.94%, all P < 0.01, Fig. 9A). Consistent results were obtained in H460, H1299 and PC9 cell lines, indicating that HOXA11-AS could clearly inhibit apoptosis in these 4 NSCLC cell lines (Fig. 9B–D).

Additionally, flow cytometry was used to measure the effect of HOXA11-AS on cell cycle distribution. In A549 cells, the results revealed that HOXA11-AS RNAi-54 caused cell cycle arrest on G2/M phase, whereas HOXA11-AS RNAi-55 caused cell cycle arrest G0/G1 phase compared with the lenti-control virus group (all P < 0.05). No significant fluctuation was found in S phase among the 3 groups (HOXA11-AS RNAi-54, HOXA11-AS RNAi-55, HOXA11-AS RNAi-56, Fig. 10A). Furthermore, in H460 and H1299 cells, HOXA11-AS RNAi-54 caused cell cycle arrest on G0/G1 phase, whereas in PC9 cells, a clear cycle arrest on G2/M phase in the HOXA11-AS RNAi-54 group was reduced (Fig. 10B–D). Considering the motivating effect of HOXA11-AS on proliferation, a rational inference was made that HOXA11-AS could improve the proliferation of NSCLC, in part because HOXA11-AS activated the cell cycle process.

HOXA11-AS promotes NSCLC tumorigenesis and angiogenesis in vivo. Tumor formation experiments in a CAM model with A549, H460, H1299 and PC9 cells were conducted to assess the effect of HOXA11-AS on tumorigenesis and angiogenesis in vivo. The results showed that both the lenti-control virus group and HOXA11-AS RNAi group could form tumor xenografts, and the tumorigenic and angiogenic ability of all 4 cell lines was weakened by HOXA11-AS RNAi (P < 0.05). In A549 cells, the size of the tumor xenografts was...
Figure 9. HOXA11-AS RNAi promoted apoptosis in A549, H1299, H460 and PC9 cell lines based on a flow cytometry assay. (Note: control, lenti-control virus). (A) Comparison of the apoptosis rate and mortality rate of A549 cells after silencing HOXA11-AS expression (*P < 0.05, **P < 0.01, ***P < 0.001). (B) Comparison of the apoptosis rate and mortality rate of H460 cells after silencing HOXA11-AS expression (*P < 0.05, **P < 0.01, ***P < 0.001). (C) Comparison of the apoptosis rate and mortality rate of H1299 cells after silencing HOXA11-AS expression (*P < 0.05, **P < 0.01, ***P < 0.001). (D) Comparison of the apoptosis rate and mortality rate of PC9 cells after silencing HOXA11-AS expression (*P < 0.05, **P < 0.01, ***P < 0.001).

Figure 10. The cell cycle distribution of A549, H460, H1299 and PC9 cells after silencing HOXA11-AS expression. (Note: control, lenti-control virus) (A) A549 cells, (B) H460 cells, (C) H1299 cells, (D) PC9 cells.
significantly reduced after transfection with HOXA11-AS RNAi-54 (127.1 ± 232.728 mm³ vs 528.667 ± 382.206 mm³, \( t = -2.008, P = 0.045 \)) compared with the lenti-control virus group. In addition to the effect on tumor size, the HOXA11-AS RNAi-54 group also exhibited a decreased vascular area ratio (7.396 ± 3.266) of tumor formation in chick chorioallantoic membrane compared to the lenti-control virus group (17.867 ± 5.795, \( t = 3.575, P = 0.006 \), Fig. 11). Furthermore, based on hematoxylin/eosin (HE) staining, we found that the original morphology of NSCLC cells was maintained in tumor xenografts. In addition, inflammatory cells and noticeable necrosis were found in pathological sections of the tumor xenografts (Fig. 12).

The potential pathways associated with HOXA11-AS. An in silico analysis was performed to explore HOXA11-AS-associated biological pathways based on MEM^21, 22 and the DAVID Bioinformatics Tool^23, 24. We collected the top 1500 co-expressed genes in different probe sets for HOXA11-AS (230666_AT and 239950_AT) as previously reported^25, 26. Then, the 574 correlated genes overlapping in these two probe sets were selected for the downstream analysis (Fig. 13). Furthermore, we explored gene potential functional enrichment by Gene ontology (GO) analysis based on these 574 HOXA11-AS co-expressed genes. Then, the significant enriched biological terms were identified by the threshold of \( P \)-value less than 0.05. Consequently, positive regulation of transcription from RNA polymerase was revealed to be the most strongly enriched biological term. Nobly, the result also

Figure 11. The A549 cell tumor formation in the chick chorioallantoic membrane after transfecting A549 cells with HOXA11-AS RNAi. (A) Lenti-control virus group. (B) HOXA11-AS RNAi-54 group. (C) Comparison of the size of the A549 cell tumor xenografts after silencing HOXA11-AS expression (*\( P < 0.05 \)). (D) Comparison of the vascular area ratio of the A549 cell tumor xenografts after silencing HOXA11-AS expression (***\( P < 0.01 \)).
showed that regulation of cell migration, as well as extracellular space and protein binding were strongly enriched biological term, which were closely related to the progress of cancer. To better understand the functions of these co-expressed genes, a function network was constructed based on the GO analysis (Fig. 14).

In addition, the Kyoto encyclopedia of genes and genomes (KEGG) pathway analysis revealed that the HOXA11-AS co-expressed genes were significantly overrepresented in the non-small cell lung cancer pathway, supporting our aforementioned result that HOXA11-AS might play a vital role in NSCLC (Fig. 15). The top five most significant GO terms and the top ten KEGG pathway items are presented in Table 3 and Table 4. Altogether, the GO terms and KEGG pathway items reinforced the observation that HOXA11-AS might be involved in biological mechanisms in NSCLC.

Discussion

In this study, TCGA database was used to explore the differential expression of HOXA11-AS between normal lung and NSCLC tissues. QRT-PCR and flow cytometry as well as CCK-8, wound healing, migration, Matrigel invasion, and cytometry assays, were performed to determine the effect of HOXA11-AS in NSCLC cell lines. Moreover, a CAM model of NSCLC was constructed to explore the effect of HOXA11-AS on tumorigenicity and angiogenesis in NSCLC. In addition, MEM was used to further analyze the co-expressed genes and potential pathways associated with HOXA11-AS. As a result, our data confirms that HOXA11-AS was up-regulated in both lung adenocarcinoma and squamous cell carcinoma compared to normal lung tissues based on TCGA database. Additionally, we found that the AUC of HOXA11-AS was 0.878 (95% CI: 0.786–0.969) for lung adenocarcinoma and 0.962 (95% CI: 0.928–0.996) for lung squamous cell carcinoma, which predicted a diagnostic value of HOXA11-AS in NSCLC. Consistent with the results from TCGA, qRT-PCR showed an up-regulated trend in the HOXA11-AS level in NSCLC tissues compared to corresponding non-cancerous lung tissues. To further explore the biological role of HOXA11-AS expression in vitro and in vivo, we found that HOXA11-AS was overexpressed in all of the 4 NSCLC cell lines (A549, H460, H1299 and PC9). Then, we performed various experiments to confirm that HOXA11-AS was a tumorigenic gene. The proliferation, migration, invasion and tumorigenic and angiogenic ability of NSCLC cells were all inhibited and apoptosis was induced after silencing the expression of HOXA11-AS. Migration and invasion is the prerequisite for tumor metastasis. Our results indicate that HOXA11-AS might be associated with metastasis in NSCLC. After examining apoptosis and cell cycle distribution by flow cytometry, a rational inference was made that HOXA11-AS RNAi could suppress the proliferation of NSCLC in part because HOXA11-AS RNAi caused cell cycle arrest on different phases. Phases such as G1/G0, S, and G2/M represent the different steps during cell proliferation. In our study, HOXA11-AS knockdown causes G0/G1 or G2/M arrest and cell cycle could not progress to the following phase, which indicate that the silencing of HOXA11-AS inhibit cell cycle progression, also, the different phenotypes of HOXA11-AS RNAi may cause a minor difference on different phases arrest.
addition, as reported, deregulated cell-cycle control is a fundamental aspect for the treatment of malignancies. Up to now, the detailed molecular mechanisms by which HOXA11-AS affect cell cycle remain elusive. Cyclin, p53, p21, p27 and transcription factor Sp1 were all involved in different phases of the cycle as reported. The difference expression of these cell-cycle regulation proteins over time might be associated with cell-cycle arrest and apoptotic cell death. However, further studies are needed to fully identify the mechanism how HOXA11-AS regulate cell cycle. In addition, angiogenesis is the basis of tumor growth, metastasis, invasion and recidivism, and the results of the CAM model confirmed that the tumorigenic and angiogenic ability of NSCLC cells was weakened after silencing the expression of HOXA11-AS, indicating that HOXA11-AS has a promoting effect on angiogenesis. These results suggest that HOXA11-AS can act as an oncogene to accelerate malignant progression and metastasis of NSCLC. In addition, GO analysis of the co-expressed genes revealed that they were involved in complex cellular pathways, such as regulation of cell migration, extracellular space and protein binding. KEGG pathway analysis showed that the non-small cell lung cancer pathway might be involved in regulating these co-expressed genes in lung cancer. We also searched Oncomine (https://www.oncomine.org/) and the Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) database, but no positive relationship was found. HOXA11-AS is the antisense RNA of HOXA11 in HOX family genes. Most of the HOX family genes were expressed in normal lung tissues except HOXA11. Several studies have revealed that HOX11 promoter methylation is related to different tumors, such as endometrial adenocarcinoma, ovarian cancer and glioblastoma. Methylation of HOXA11 was significantly associated with poor prognosis in cancer patients. In our current study, we found that HOXA11-AS was expressed in both NSCLC tissues and non-cancerous lung tissues, and an up-regulated trend in the HOXA11-AS level in NSCLC.
tissues was found compared to corresponding normal lung tissues. Additionally, HOXA11-AS was expressed in different NSCLC cell lines (A549, H460, H1299 and PC9). Weak expression of HOXA11-AS was also detected in normal bronchial epithelial cells, which was in contrast to the absence of HOXA11-AS expression in normal lung tissues. The main cause for this might be frequent passages, cellular senescence and the damage caused by pancreatin digestion, which leads to gene mutations in cells. However, a larger sample size is needed to verify our results.

To date, several studies have reported the expression of HOXA11-AS in different types of cancer, such as gastric cancer, ovarian cancer, glioma, colorectal cancer, cervical cancer and NSCLC20, 38–44. For example, Sun39 et al. demonstrated that HOXA11-AS could affect cell growth, migration, invasion and apoptosis of gastric cancer by analyzing microarray data and performing a series of experiments in vitro and in vivo. Additionally, Sun39 et al. investigated the potential mechanism of HOXA11-AS in gastric cancer cells, and they found that HOXA11-AS could play an oncogenic role through the EZH2/HOXA11-AS/LSD1 complex or HOXA11-AS/miR-1297/EZH2 crosstalk. Richards43 et al. found that HOXA11-AS is a tumor-suppressive lncRNA related to epithelial ovarian cancer cell proliferation and survival by exploring genome-wide association study data and performing various functional studies. Richards43 et al. also revealed that the effects of HOXA11-AS in ovarian cancer could be modified by germline variants. Kim40 et al. examined the HOXA11-AS expression in cervical cancer and the bio-functional effect of HOXA11-AS in vitro and in vivo, and they found that HOXA11-AS overexpression enhanced cell proliferation, migration and invasion in vitro, whereas in vivo xenograft experiments indicated that HOXA11-AS strongly induced tumor growth. Wang42 et al. applied a high-throughput microarray and gene set enrichment analysis to confirm that HOXA11-AS is associated with cell cycle and could act as a biomarker in progression of glioma. In addition, they found that HOXA11-AS could affect p16, p21 and p27 expression via competitive endogenous RNAs, epigenetic modification, or chromatin modification methods to regulate proliferation and cell cycle of glioma cells. In this study, HOXA11-AS was shown to be an oncogenic lncRNA in NSCLC, but the molecular mechanism of HOXA11-AS in NSCLC remains unclear. GO and KEGG analysis of the co-expressed genes of HOXA11-AS revealed that they were involved in complex cellular pathways, such as regulation of cell migration, extracellular space and protein binding, as well as the non-small cell lung cancer pathway. We hypothesize that HOXA11-AS could affect proliferation, migration, apoptosis and cell cycle of NSCLC, in part because HOXA11-AS affected the non-small cell lung cancer pathway, such as the ErbB signaling pathway, PI3K-Akt signaling pathway and MAPK signaling pathway. An inappropriate activation of K-Ras, EGFR, RARB and RASSF1 might lead to the development of NSCLC. In addition, our data confirm for the first time the clinical significance and effect of HOXA11-AS on biological processes in NSCLC. The concrete molecular mechanism involved, specifically, whether HOXA11-AS plays pivotal roles in tumorigenesis and
deterioration of NSCLC through regulating specific genes or as competitive endogenous RNA for specific miRNAs, still requires further elucidation through functional experiments.

Conclusions

Our findings demonstrate that HOXA11-AS plays a significant role in NSCLC proliferation, invasion, migration, apoptosis and cell cycle. We also found that the HOXA11-AS was associated with tumorigenesis and angiogenesis in NSCLC. We speculate that HOXA11-AS may play a significant role in NSCLC carcinogenesis and progression by modulating the non-small cell lung cancer pathway. However, the exact molecular mechanism should be verified by future functional experiments.

Materials and Methods

Evaluation of the clinical value of HOXA11-AS in NSCLC. Significance of HOXA11-AS in NSCLC based on TCGA data. The Cancer Genome Atlas (TCGA) (http://cancergenome.nih.gov) database is one of the largest available public platforms, providing genomic, transcriptomic, methylomic and copy number variation (CNV) data sets for more than 20 cancer types45–48. TCGA can also be used to further research the complicated cancer genomics and various clinical parameters49, 50. In the current study, we downloaded the original data of RNASeqV2 in NSCLC, which consists of lung adenocarcinoma patients (535 lung adenocarcinoma cases vs 49 non-cancerous lung cases) and lung squamous cell carcinoma patients (502 lung squamous cell carcinoma cases vs 49 non-cancerous lung cases) from TCGA database (March, 31, 2017). Then the patients with the expression of HOXA11-AS less than 1 were excluded and the expression of HOXA11-AS was normalized by log2 transformed for the further analysis. Then, the expression of HOXA11-AS and the corresponding clinical parameters of the patients were extracted.

Quantitative real-time PCR. A total of 20 NSCLC cases, between January 2015 and August 2016, were collected from the Department of Pathology, First Affiliated Hospital of the Guangxi Medical University (Nanning, Guangxi, China). The average age of these patients was 55 years old (ranging from 38 to 79 years). All these cases were selected randomly from cases of surgical resection without treatment. All methods were carried out in accordance with relevant guidelines and regulations. And all experimental protocols were approved by the Ethical Committee of the First Affiliated Hospital of Guangxi Medical University, and consent forms were signed by the clinicians and patients for the use of the tissues for study. All the samples were confirmed by two independent pathologists who did not know the detailed patient information.

Total RNA was extracted using a Takara PrimeScript RT reagent Kit (Code: 9767) according to the manufacturer’s instructions. The extracted RNA was used for complementary DNA synthesis with a Takara PrimeScript RT Reagent Kit (Code: RR047A) according to the kit instructions. Then, qRT-PCR was performed using a LightCycler 480 Real-time PCR System (Roche, Shanghai). The primer pairs applied for PCR were as follows: HOXA11-AS, 5'-CGGCTAACAAGGAGATTGTTG-3' (forward) and 5'-AGGCTCAAGGAGATTGTTG-3' (reverse); GAPDH, 5'-ACCCACTCCTCACCTTTG-3' (forward) and 5'-CTCTGTGCTCCTGTGGA-3' (reverse). One PCR cycle included 95 °C for 10 seconds, 60 °C for 20 seconds, 72 °C for 20 seconds. Expression

Figure 15. HOXA11-AS co-expressed genes were significantly overrepresented in the non-small cell lung cancer pathway, revealed by KEGG pathway analysis52–54 (http://www.kegg.jp/kegg/kegg1.html).
data were normalized to GAPDH to guarantee stability of the expression levels. The relative value of HOXA11-AS expression was standardized using the formula of $2^{-\Delta\Delta CT}$.

### Exploration of the effect of HOXA11-AS on biological processes in NSCLC.

In Vitro experiments. Cell culture and Transfection: The human NSCLC cell lines A549, H460, 1299 and PC9 were purchased from the Type Culture Collection of the Chinese Academy of Sciences, Shanghai, China. All the NSCLC cell lines were cultured with 10% heat-inactivated fetal bovine serum (Invitrogen Corp, Grand Island, NY, USA) under 5% CO$_2$ atmosphere with 2 mM gentamicin at 37°C. The exponentially growing cells were used for the following experiments. For transfection, an effective shRNA targeting to HOXA11-AS was cloned into the plasmids
were considered statistically significant. In addition, all experiments were performed in triplicate. Survival curve were evaluated using a log-rank test and drawn using Kaplan–Meier method. P values less than 0.05 were considered statistically significant. Clinical diagnostic value of HOXA11-AS was analyzed by a ROC curve. Differences in the expression of HOXA11-AS, we used an open-access resource, Multi Experiment Matrix (MEM, http://biit.cs.ut.ee/mem/index.cgi), to interactively explore the co-expressed genes for HOXA11-AS based on an Affymetrix Gene Chip Human Genome U133 Plus 2.0 Array platform. Then, functional enrichment analyses at the GO and KEGG pathway level were conducted to infer HOXA11-AS co-expressed gene function by respectively using the DAVID Bioinformatics Tool (https://david.ncifcrf.gov/, version 6.7) and KOBAS 2.0 (http://kobas.cbi.pku.edu.cn/). Both the GO enrichment and KEGG pathway analysis were performed by Fischer's exact test. In this process, three independent categories derived from the GO analysis were included: biological process (BP), cellular component (CC) and molecular function (MF).

**Statistical analysis.** All statistical analyses were performed using Statistical Package SPSS 22.0. In addition, comparison between two samples was analyzed by Student’s t-test. Comparison between groups was performed using one-way analysis of variance (ANOVA). For non-normally distributed variables, we performed Mann-Whitney U test and summary statistics were expressed as the mean ± standard deviation (Mean ± SD). The relationships between HOXA11-AS expression and the clinicopathological parameters were assessed by Spearman’s rank correlation. The clinical diagnostic value of HOXA11-AS was analyzed by a ROC curve. Differences in the survival curve were evaluated using a log-rank test and drawn using Kaplan–Meier method. P values less than 0.05 were considered statistically significant. In addition, all experiments were performed in triplicate.

**Statement.** All methods were carried out in accordance with relevant guidelines and regulations. And all experimental protocols were approved by the Ethical Committee of the First Affiliated Hospital of Guangxi Medical University. Patients provide informed consent authorizing the use of their personal information and tissues for research purposes. Also, this study was fully compliance with the publication guidelines provided by TCGA and the approval of ethics committee was not required.
References
1. Navarajgan, G., Berriault, C., Do, M., Villeneuve, P. J. & Demers, P. A. Cancer incidence and mortality from exposure to radon progeny among Ontario uranium miners. Occupational and environmental medicine, doi:10.1136/oem.2016-103836 (2016).
2. Kang, C. G., Lee, H. J., Kim, S. H. & Lee, E. O. Zerumbone Suppresses Osteopontin-Induced Cell Invasion Through Inhibiting the FAK/AKT/ROCK Pathway in Human Non-Small Cell Lung Cancer A549 Cells. Journal of natural products 79, 156–160, doi:10.1021/acs.jnatprod.6b00796 (2016).
3. Miller, K. D. et al. Cancer treatment and survivorship statistics, 2016. CA: a cancer journal for clinicians 66, 271–289, doi:10.3322/caac.21349 (2016).
4. Xu, G. et al. Long noncoding RNA expression profiles of lung adenocarcinoma ascertained by microarray analysis. PLoS One 9, e104044, doi:10.1371/journal.pone.0104044 (2014).
5. Jemal, A. et al. Cancer statistics, 2009. CA: a cancer journal for clinicians 59, 225–249, doi:10.3322/caac.20006 (2009).
6. Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer 127, 2893–2917, doi:10.1002/ijc.25516 (2010).
7. Chen, G. et al. miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. PLoS One 8, e60317, doi:10.1371/journal.pone.0060317 (2013).
8. Xie, K. et al. Gene expression profiling of microRNAs associated with UCA1 in bladder cancer cells. International journal of oncology 48, 1617–1627, doi:10.3892/ijo.2016.3357 (2016).
9. Zhao, G., Su, Z., Song, D., Mao, Y. & Mao, X. The long noncoding RNA MALAT1 regulates the lipopolysaccharide-induced inflammatory response through its interaction with NF-kappaB. FEBS letters 589, 2884–2895, doi:10.1002/1873-3468.12315 (2016).
10. Daneshvar, K. et al. DIGIT Is a Conserved Long Noncoding RNA That Regulates GSC Expression to Control Definitive Endoderm Differentiation of Embryonic Stem Cells. Cell reports 17, 353–365, doi:10.1016/j.celrep.2016.09.017 (2016).
11. Wei, X. et al. Long noncoding RNA ANRIL is activated by hypoxia-inducible factor-1alpha and promotes osteosarcoma cell invasion and suppresses cell apoptosis upon hypoxia. Cancer cell international 16, 73, doi:10.1186/s12935-016-0349-7 (2016).
12. Sun, L., Sun, P., Zhou, Q. Y., Gao, X. & Han, Q. Long noncoding RNA MALAT1 promotes uveal melanoma cell growth and invasion by silencing of miR-140. American journal of translational research 8, 3939–3946 (2016).
13. Li, Z. et al. The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer. Cell death and differentiation. doi:10.1038/cdd.2016.85 (2016).
14. Schmitt, L. H. et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 6, 1984–1992, doi:10.1097/JTO.0b013e3182307eac (2011).
15. Gutschner, T. et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer research 73, 1180–1189, doi:10.1158/0008-5472.CAN-12-2850 (2013).
16. Schmitt, L. H. et al. Prognostic impact of Bcl-2 depends on tumor histology and expression of MALAT-1 lncRNA in non-small-cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 9, 1294–1304, doi:10.1097/JTO.0000000000000243 (2014).
17. He, J. et al. Snail-activated long non-coding RNA PCA3 up-regulates PRKD3 expression by miR-1261 sponging, thereby promotes invasion and migration of prostate cancer cells. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 33, 13277-016-5450-y (2016).
18. Wang, X. et al. Silencing of long noncoding RNA MALAT1 by miR-101 and miR-217 inhibits proliferation, migration, and invasion of esophageal squamous cell carcinoma cells. The Journal of biological chemistry 290, 3925–3935, doi:10.1074/jbc.M114.596866 (2015).
19. Zheng, L. L. et al. deepBase v2.0: identification, expression, evolution and function of small RNAs, LncRNAs and circular RNAs from deep-sequencing data. Nucleic acids research 44, D196–202, doi:10.1093/n.Set1271 (2016).
20. Zhang, Y. et al. Comprehensive analysis of the long noncoding RNA HOXA11-AS gene interaction regulatory network in NSCLC cells. Cancer cell international 16, 89, doi:10.1186/s12935-016-0366-6 (2016).
21. Adler, P. et al. Mining for coexpression across hundreds of datasets using novel rank aggregation and visualization methods. Genome biology 10, R39, doi:10.1186/gb-2009-10-12-r39 (2009).
22. Koldziej, R., Laur, S., Adler, P. & Vilo, J. Robust rank aggregation for gene list integration and meta-analysis. Bioinformatics (Oxford, England) 28, 573–580, doi:10.1093/bioinformatics/btq709 (2012).
23. Huang da, W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic acids research 37, 1–13, doi:10.1093/nar/gkn923 (2009).
24. Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature protocols 4, 44–57, doi:10.1038/nprot.2008.81 (2009).
25. Zeng, J. H. et al. Comprehensive investigation of a novel differentially expressed lncRNA expression profile signature to assess the survival of patients with colorectal adenocarcinoma. Oncotarget 8, 16811–16828, doi:10.18632/oncotarget.15161 (2017).
26. Tang, R. X. et al. Identification of a RNA-Seq based prognostic signature with five IncRNAs for lung squamous cell carcinoma. Oncotarget, doi:10.18632/oncotarget.17098 (2017).
27. Han, D. et al. Antitumorigenic effect of atmospheric-pressure dielectric barrier discharge on human colorectal cancer cells via regulation of Sp1 transcription factor. Scientific reports 7, 43081, doi:10.1038/srep43081 (2017).
28. Sendrowicz, A. M. Cell cycle modulators for the treatment of lung malignancies. Clinical lung cancer 5, 158–168, doi:10.3816/ CLC.2003.a.023 (2003).
29. Feizi, M., Slayanti, C., Ben-Attia, M., Lang, F. & Jennaa, M. Purified Lesser weever fish venom (Trachinus vipera) induces eryptosis, apoptosis and cell cycle arrest. Scientific reports 6, 30288, doi:10.1038/srep30288 (2016).
30. Guo, H. et al. Litchi seed extracts diminish prostate cancer progression via induction of apoptosis and attenuation of EMT through Akt/GSK-3beta signaling. Scientific reports 7, 41656, doi:10.1038/srep41656 (2017).
31. Rhodes, D. R. et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9, 166–180 (2007).
32. Clough, E. & Barrett, T. The Gene Expression Omnibus Database. Methods in molecular biology (Clifton, N.J.) 1418, 93–110, doi:10.1007/978-1-4939-3578-9_3 (2016).
33. Golpon, H. A. et al. HOX genes in human lung: altered expression in primary pulmonary hypertension and emphysema. The American journal of pathology 158, 955–966, doi:10.1016/S0002-9440(10)64042-4 (2001).
34. Whitcomb, B. P. et al. Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in glioblastoma. Journal of neuro-oncology 113, 441–449, doi:10.1007/s11060-013-1123-3 (2013).
35. Hwang, J. A. et al. HOXA11 hypermethylation is associated with progression of non-small cell lung cancer. Oncotarget 4, 2317–2325, doi:10.18632/oncotarget.1464 (2013).
Scientific Reports | www.nature.com/scientificreports

38. Li, T. et al. Expression and clinicopathological significance of the IncRNA HOXA11-AS in colorectal cancer. *Oncology letters* **12**, 4155–4160, doi:10.3892/ol.2016.5129 (2016).

39. Sun, M. et al. lncRNA HOXA11-AS Promotes Proliferation and Invasion of Gastric Cancer by Scaffolding the Chromatin Modification Factors PRC2, LSD1, and DNMT1. *Cancer research* **76**, 6299–6310, doi:10.1158/0008-5472.CAN-16-0356 (2016).

40. Kim, H. J. et al. The long noncoding RNA HOXA11 antisense induces tumor progression and stemness maintenance in cervical cancer. *Oncotarget* **7**, 83001–83016, doi:10.18632/oncotarget.12863 (2016).

41. Se, Y. B. et al. Underexpression of HOXA11 is Associated with Treatment Resistance and Poor Prognosis in Glioblastoma. *Cancer research and treatment: official journal of Korean Cancer Association*, doi:10.4143/crt.2016.106 (2016).

42. Wang, Q. et al. A novel cell cycle-associated IncRNA, HOXA11-AS, is transcribed from the 5′-prime end of the HOXA transcript and is a biomarker of progression in glioma. *Cancer letters* **373**, 231–259, doi:10.1016/j.canlet.2016.01.039 (2016).

43. Richards, E. J. et al. A functional variant in HOXA11-AS, a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancer. *Oncotarget* **6**, 34745–34757, doi:10.18632/oncotarget.5784 (2015).

44. Chen, J. et al. Systematic gene microarray analysis of the IncRNA expression profiles in human uterine cervix carcinoma. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie* **72**, 83–90, doi:10.1016/j.biopharma.2015.04.010 (2015).

45. Deng, M., Bragelmann, J., Schulz, J. L. & Perner, S. Web-TCGA: an online platform for integrated analysis of molecular cancer data sets. *BMC bioinformatics* **17**, 72, doi:10.1186/s12859-016-0917-9 (2016).

46. Kranov, G. S. et al. CrossHub: a tool for multi-way analysis of The Cancer Genome Atlas (TCGA) in the context of gene expression regulation mechanisms. *Nucleic acids research* **44**, e62, doi:10.1093/nar/gkv478 (2016).

47. Higashiguchi, M. et al. Clarifying the biological significance of the CHK2 K373E somatic mutation discovered in The Cancer Genome Atlas (TCGA) database. *FEBS letters* **580**, 3468–3472, doi:10.1016/j.febslet.2014.12.001 (2016).

48. Shukla, S. et al. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma. *Journal of the National Cancer Institute* **109**, doi:10.1093/jnci/djw201 (2017).

49. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer discovery* **2**, 401–404, doi:10.1158/2159-8290.CD-12-0095 (2012).

50. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cbioPortal. *Science signaling* **6**, p1, doi:10.1126/scisignal.2004098 (2013).

51. Xiao, Y. et al. RNF7 knockdown inhibits prostate cancer tumorigenesis by inactivation of ERK1/2 pathway. *Scientific reports* **7**, 43683, doi:10.1038/srep43683 (2017).

52. Zhou, W. et al. Discovery and Optimization of N-Substituted 2-(4-pyridinyl)thiazole carboxamides against Tumor Growth through Regulating Angiogenesis Signaling Pathways. *Scientific reports* **6**, 33434, doi:10.1038/srep33434 (2016).

53. Xiao, X. et al. Chick Chorioallantoic Membrane Assay: A 3D Animal Model for Study of Human Nasopharyngeal Carcinoma. *PLoS One* **10**, e0130935, doi:10.1371/journal.pone.0130935 (2015).

54. Xie, C. et al. KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases. *Nucleic acids research* **39**, W316–322, doi:10.1093/nar/gkw104 (2011).

55. Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y. & Morishima, K. KEGG: new perspectives on genomes, pathways, diseases and regulation mechanisms. *Nucleic acids research* **45**, W317–324, doi:10.1093/nar/gkw427 (2017).

56. Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference resource for gene and protein annotation. *Nucleic acids research* **44**, D457–462, doi:10.1093/nar/gkv1070 (2016).

57. Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic acids research* **28**, 27–30 (2000).

Acknowledgements

This study was supported by funds from the National Natural Science Foundation of China (NSFC81560469, NSFC81360327, NSFC81660488 and NSFC81560448), funds from the Guangxi Provincial Health Bureau Scientific Research Project (Z2013201), and from the Natural Science Foundation of Guangxi, China (2015GXNSFCA139090). The authors acknowledge the data provided by TCGA database. Yu Zhang and Wen-jie Chen contributed equally as co-first authors. Dian-zhong Luo and Gang Chen contributed equally as co-corresponding authors of this paper. The funders had no role in the study design, the data collection and analysis, the decision to publish, or the preparation of the manuscript.

Author Contributions

Y.Z. and W.C. participated in clinical data analysis and drafted the manuscript. T.G., G.C. and D.L. participated in the statistical analysis and corrected the manuscript. Z.X. and X.Z. prepared for the specimens, carried out the siRNA isolation. Y.D., Z.W., Z.Y. and K.C. performed the statistical analysis, prepared for the figures and revised the manuscript. S.L., D.L., G.C. and T.G. conceived of the study, participated in design and coordination and corrected the manuscript. All authors read and approved the final manuscript.

Additional Information

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017.